GE Healthcare Speeds Assay Development with Pre-Validated Conditions for GPCR Studies
The new SPA GPCR Assays offer researchers working in high throughput screening environments pre-developed assay conditions for GPCR receptor-ligand binding studies.
"GE Healthcare is continually working to help cut development time throughout the drug discovery process," comments John Sutton, vice president product management, cell analysis & screening at GE Healthcare. "This is the first time that SPA GPCR protocols have been available in this way. By providing ready-made optimum assay conditions for GPCR ligand binding studies, GE Healthcare is reducing assay development process time for researchers, therefore enabling them to focus on screening potential drug candidates."
These SPA GPCR Assays broaden GE Healthcare's SPA range and comprise SPA beads and radioligands from GE Healthcare with GPCR receptor membranes from Euroscreen S.A., as well as a pre-validated protocol describing the required procedure for the GPCR assay.
Other news from the department research and development
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.